IL157103A - Process for the preparation of the tartrate salt of (3aR) - 2, 3a, 4, 5, 6, 7 - hexahydro - 2 - methyl - 3a (phenylmethyl) - H3 - pyrazolo [c – 3,4] pyridine - 3 - on - Google Patents

Process for the preparation of the tartrate salt of (3aR) - 2, 3a, 4, 5, 6, 7 - hexahydro - 2 - methyl - 3a (phenylmethyl) - H3 - pyrazolo [c – 3,4] pyridine - 3 - on

Info

Publication number
IL157103A
IL157103A IL157103A IL15710300A IL157103A IL 157103 A IL157103 A IL 157103A IL 157103 A IL157103 A IL 157103A IL 15710300 A IL15710300 A IL 15710300A IL 157103 A IL157103 A IL 157103A
Authority
IL
Israel
Prior art keywords
methyl
acid
oxo
formula
compound
Prior art date
Application number
IL157103A
Other languages
English (en)
Hebrew (he)
Other versions
IL157103A0 (en
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of IL157103A0 publication Critical patent/IL157103A0/xx
Publication of IL157103A publication Critical patent/IL157103A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0202Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/02Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06191Dipeptides containing heteroatoms different from O, S, or N
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
IL157103A 1999-02-26 2000-02-17 Process for the preparation of the tartrate salt of (3aR) - 2, 3a, 4, 5, 6, 7 - hexahydro - 2 - methyl - 3a (phenylmethyl) - H3 - pyrazolo [c – 3,4] pyridine - 3 - on IL157103A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12274599P 1999-02-26 1999-02-26
IL134599A IL134599A (en) 1999-02-26 2000-02-17 A process for making amide substances that cause the secretion of growth hormone

Publications (2)

Publication Number Publication Date
IL157103A0 IL157103A0 (en) 2004-02-08
IL157103A true IL157103A (en) 2007-07-24

Family

ID=22404505

Family Applications (2)

Application Number Title Priority Date Filing Date
IL134599A IL134599A (en) 1999-02-26 2000-02-17 A process for making amide substances that cause the secretion of growth hormone
IL157103A IL157103A (en) 1999-02-26 2000-02-17 Process for the preparation of the tartrate salt of (3aR) - 2, 3a, 4, 5, 6, 7 - hexahydro - 2 - methyl - 3a (phenylmethyl) - H3 - pyrazolo [c – 3,4] pyridine - 3 - on

Family Applications Before (1)

Application Number Title Priority Date Filing Date
IL134599A IL134599A (en) 1999-02-26 2000-02-17 A process for making amide substances that cause the secretion of growth hormone

Country Status (44)

Country Link
US (2) US6541634B2 (US07585860-20090908-C00112.png)
EP (2) EP1031575B1 (US07585860-20090908-C00112.png)
JP (3) JP3437813B2 (US07585860-20090908-C00112.png)
KR (2) KR100372063B1 (US07585860-20090908-C00112.png)
CN (3) CN1837205A (US07585860-20090908-C00112.png)
AP (1) AP1221A (US07585860-20090908-C00112.png)
AR (2) AR029617A1 (US07585860-20090908-C00112.png)
AT (1) ATE277944T1 (US07585860-20090908-C00112.png)
AU (1) AU764122B2 (US07585860-20090908-C00112.png)
BG (1) BG104175A (US07585860-20090908-C00112.png)
BR (2) BRPI0017522B8 (US07585860-20090908-C00112.png)
CA (1) CA2299495C (US07585860-20090908-C00112.png)
CO (1) CO5160252A1 (US07585860-20090908-C00112.png)
DE (1) DE60014212T2 (US07585860-20090908-C00112.png)
DK (1) DK1031575T3 (US07585860-20090908-C00112.png)
DZ (1) DZ3018A1 (US07585860-20090908-C00112.png)
EA (1) EA003218B1 (US07585860-20090908-C00112.png)
EE (1) EE200000193A (US07585860-20090908-C00112.png)
ES (1) ES2226712T3 (US07585860-20090908-C00112.png)
GT (1) GT200000018A (US07585860-20090908-C00112.png)
HK (1) HK1030219A1 (US07585860-20090908-C00112.png)
HN (1) HN2000000021A (US07585860-20090908-C00112.png)
HR (1) HRP20000103A2 (US07585860-20090908-C00112.png)
HU (1) HUP0000907A3 (US07585860-20090908-C00112.png)
ID (1) ID24861A (US07585860-20090908-C00112.png)
IL (2) IL134599A (US07585860-20090908-C00112.png)
IN (1) IN192352B (US07585860-20090908-C00112.png)
IS (1) IS5380A (US07585860-20090908-C00112.png)
MA (1) MA25072A1 (US07585860-20090908-C00112.png)
NO (1) NO20000965L (US07585860-20090908-C00112.png)
NZ (1) NZ503062A (US07585860-20090908-C00112.png)
OA (1) OA11325A (US07585860-20090908-C00112.png)
PA (1) PA8491201A1 (US07585860-20090908-C00112.png)
PE (1) PE20001550A1 (US07585860-20090908-C00112.png)
PL (1) PL338628A1 (US07585860-20090908-C00112.png)
PT (1) PT1031575E (US07585860-20090908-C00112.png)
SG (1) SG90096A1 (US07585860-20090908-C00112.png)
SI (1) SI1031575T1 (US07585860-20090908-C00112.png)
SK (1) SK284982B6 (US07585860-20090908-C00112.png)
TN (1) TNSN00035A1 (US07585860-20090908-C00112.png)
TR (1) TR200000536A2 (US07585860-20090908-C00112.png)
TW (2) TWI286142B (US07585860-20090908-C00112.png)
UA (1) UA70306C2 (US07585860-20090908-C00112.png)
ZA (1) ZA200000888B (US07585860-20090908-C00112.png)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1132388A3 (en) * 2000-03-09 2004-03-03 Pfizer Products Inc. Hexahydropyrazolo[4,3-c]pyridine metabolites
CA2410597A1 (en) 2000-05-30 2001-12-06 Merck & Co., Inc. Melanocortin receptor agonists
AU2003237595A1 (en) * 2003-05-26 2004-12-13 Biocon Limited Process for the preparation of s(+)-2-ethoxy-4-(n-{1-(2-piperidinophelyl)-3-methyl-1- butyl} aminocarbonylmethyl)benzoic acid derivatives
WO2005027913A1 (en) * 2003-09-19 2005-03-31 Pfizer Products Inc. Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and a growth hormone secretagogue
US9117477B2 (en) 2013-05-08 2015-08-25 HGST Netherlands B.V. Perpendicular magnetic recording media having novel seed layer
RU2670978C9 (ru) * 2013-05-28 2018-11-22 Раквалиа Фарма Инк. Полиморфные формы
CN109320515A (zh) * 2018-11-22 2019-02-12 常州大学 一种Capromorelin手性中间体的不对称合成方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8610980D0 (en) 1986-05-06 1986-06-11 Ici America Inc Heterocyclic fused tricyclic compounds
GB8901423D0 (en) 1989-01-23 1989-03-15 Fujisawa Pharmaceutical Co Pyrazolopyridine compound and processes for preparation thereof
US5578593A (en) 1992-12-11 1996-11-26 Merck & Co., Inc. Spiro piperidines and homologs promote release of growth hormone
PL322706A1 (en) 1993-11-09 1998-02-16 Merck & Co Inc Piperidines, pyrolidines and hexahydro-1h-azepins enhancing growth hormone liberation
US5609150A (en) 1995-04-18 1997-03-11 Maged; Jeffrey M. Method for dilating respiratory passages
TW432073B (en) 1995-12-28 2001-05-01 Pfizer Pyrazolopyridine compounds
WO1997034604A1 (en) 1996-03-21 1997-09-25 Merck & Co., Inc. 4-spiroindoline piperidines promote release of growth hormone
WO1997036873A1 (en) 1996-04-03 1997-10-09 Merck & Co., Inc. Piperidines, pyrrolidines and hexahydro-1h-azepines promote release of growth hormone
AU7445498A (en) 1997-06-25 1999-01-04 Pfizer Inc. Dipeptide derivatives as growth hormone secretagogues
UA53716C2 (uk) 1997-06-25 2003-02-17 Пфайзер Продактс Інк. Тартратна сіль заміщеного дипептиду, спосіб її одержання, проміжні сполуки та спосіб їх одержання, фармацевтична композиція (варіанти), спосіб підвищення рівнів ендогенного гормону росту та спосіб лікування або профілактики захворювань (варіанти)
UA64751C2 (uk) 1997-06-25 2004-03-15 Пфайзер Продактс Інк. Спосіб лікування інсулінової толерантності речовинами, які посилюють секрецію гормону росту (варіанти) та фармацевтична композиція (варіанти)

Also Published As

Publication number Publication date
AP1221A (en) 2003-11-03
BRPI0000967B8 (pt) 2021-12-07
HN2000000021A (es) 2001-02-02
CN1137891C (zh) 2004-02-11
IL134599A0 (en) 2001-04-30
TWI286142B (en) 2007-09-01
JP4051314B2 (ja) 2008-02-20
EP1449842A1 (en) 2004-08-25
IL157103A0 (en) 2004-02-08
HRP20000103A2 (en) 2001-04-30
TNSN00035A1 (fr) 2005-11-10
CA2299495A1 (en) 2000-08-26
EA200000172A3 (ru) 2000-10-30
PE20001550A1 (es) 2001-01-11
HU0000907D0 (en) 2000-04-28
EP1031575A1 (en) 2000-08-30
KR100361783B1 (ko) 2002-11-22
PA8491201A1 (es) 2001-04-30
ATE277944T1 (de) 2004-10-15
DE60014212T2 (de) 2005-12-15
JP2003261565A (ja) 2003-09-19
IS5380A (is) 2000-08-27
NZ503062A (en) 2001-07-27
AR029617A1 (es) 2003-07-10
NO20000965L (no) 2000-08-28
SI1031575T1 (en) 2005-02-28
ES2226712T3 (es) 2005-04-01
JP2003327585A (ja) 2003-11-19
KR20010006698A (ko) 2001-01-26
TR200000536A2 (tr) 2000-09-21
IN192352B (US07585860-20090908-C00112.png) 2004-04-10
JP2000247974A (ja) 2000-09-12
AR053722A2 (es) 2007-05-16
BRPI0000967A (pt) 2001-09-11
CN1270960A (zh) 2000-10-25
IL134599A (en) 2006-12-10
US6673929B2 (en) 2004-01-06
KR100372063B1 (ko) 2003-02-14
CO5160252A1 (es) 2002-05-30
BRPI0017522A2 (US07585860-20090908-C00112.png) 2009-12-22
EA003218B1 (ru) 2003-02-27
BRPI0000967B1 (pt) 2012-06-12
PT1031575E (pt) 2004-11-30
GT200000018A (es) 2001-08-16
HUP0000907A3 (en) 2001-05-28
JP3437813B2 (ja) 2003-08-18
DZ3018A1 (fr) 2004-03-20
US6541634B2 (en) 2003-04-01
AP2000001754A0 (en) 2000-03-31
CA2299495C (en) 2010-06-15
DE60014212D1 (de) 2004-11-04
MA25072A1 (fr) 2000-10-01
DK1031575T3 (da) 2005-01-03
HK1030219A1 (en) 2001-04-27
US20030158414A1 (en) 2003-08-21
EE200000193A (et) 2000-10-16
EP1031575B1 (en) 2004-09-29
PL338628A1 (en) 2000-08-28
KR20020065455A (ko) 2002-08-13
CN1515570A (zh) 2004-07-28
UA70306C2 (en) 2004-10-15
OA11325A (en) 2003-10-27
SK284982B6 (sk) 2006-03-02
BRPI0017522B1 (pt) 2013-09-24
HUP0000907A2 (en) 2001-03-28
ZA200000888B (en) 2001-08-23
ID24861A (id) 2000-08-31
NO20000965D0 (no) 2000-02-25
AU1947100A (en) 2000-08-31
US20020002283A1 (en) 2002-01-03
SG90096A1 (en) 2002-07-23
TW200718702A (en) 2007-05-16
CN1837205A (zh) 2006-09-27
BG104175A (bg) 2000-12-29
EA200000172A2 (ru) 2000-08-28
AU764122B2 (en) 2003-08-07
BRPI0017522B8 (pt) 2021-05-25
SK2302000A3 (en) 2000-11-07

Similar Documents

Publication Publication Date Title
EP2066667B1 (en) Process for the preparation of pyrido[2,1-a]isoquinoline derivatives comprising optical resolution of an enamine
US20150126743A1 (en) Process For The Preparation Of Pyrido [2,1-A] Isoquinoline Derivatives Comprising Optical Resolution Of An Enamine
US6465651B2 (en) Process and intermediates for growth hormone secretagogues
EP1031575B1 (en) Process for preparing growth hormone secretagogues
CA2391013C (en) Process and intermediates to a tetrahydro-[1,8]-naphthyridine
CZ2000704A3 (cs) Způsob přípravy sloučenin podporujících sekreci růstového hormonu
MXPA00002031A (en) Process for preparing growth hormone secretagogues
JP7430297B2 (ja) N-アルキルアミノ酸、およびn-アルキルアミノ酸を含むペプチドの製造方法

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees